Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • Vascular Malformations (Apr 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
Antigen presenting cells expressing Fas ligand down-modulate chronic inflammatory disease in Fas ligand–deficient mice
Huang-Ge Zhang, … , Tong Zhou, John D. Mountz
Huang-Ge Zhang, … , Tong Zhou, John D. Mountz
Published March 15, 2000
Citation Information: J Clin Invest. 2000;105(6):813-821. https://doi.org/10.1172/JCI8236.
View: Text | PDF
Article

Antigen presenting cells expressing Fas ligand down-modulate chronic inflammatory disease in Fas ligand–deficient mice

  • Text
  • PDF
Abstract

We assessed the effect of modified antigen presenting cells (APCs) expressing high levels of Fas ligand (APC-FasL) on post-viral chronic inflammatory disease. FasL-deficient B6-gld/gld mice infected with murine cytomegalovirus (MCMV) cleared the virus from their lungs, kidneys, and livers within 2 weeks of infection. However, inflammation persisted in these organs for more than 8 weeks, with a chronically increased T-cell response to MCMV-infected APCs and production of autoantibodies. Administration of APC-AdFasL at 4 weeks suppressed this inflammation and diminished the T-cell response and autoantibody production. APC-AdFasL that had been transfected with ultraviolet-irradiated MCMV were more effective than uninfected APC-AdFasL in ameliorating the chronic inflammation. APC-AdFasL migrated preferentially to the spleen, where they triggered apoptosis of lymphocytes in the marginal zone of the spleen. These results confirm that Fas-mediated apoptosis is not required for clearance of virus, but is required for down-modulation of the virally induced chronic inflammatory response. This organwide effect of APC-AdFasL appears to be mediated by elimination of activated T lymphocytes in the spleen before their emigration to the target organs.

Authors

Huang-Ge Zhang, Martin Fleck, Earl R. Kern, Di Liu, Yongming Wang, Hui-Chen Hsu, Pingar Yang, Zheng Wang, David T. Curiel, Tong Zhou, John D. Mountz

×

Figure 2

Options: View larger image (or click on image) Download as PowerPoint
Quantitative analysis of inflammation in the lung, kidney, and liver. B6...
Quantitative analysis of inflammation in the lung, kidney, and liver. B6+/+ and B6-gld/gld mice were infected intraperitoneally with MCMV (1 × 105 pfu) and lung (top panel), kidney (middle panel), and liver (bottom panel) tissues were assessed for severity of inflammation and tissue damage on a relative scale ranging from 0 (not present) to 4 (most severe). The bar graph represents the score ± SEM of at least 5 mice analyzed at each time point.

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts